MedTrace Logo

SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer

NCT03732508 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-11-06

No results posted yet for this study

Summary

The purpose of this study is to evaluate the progression-free survival (PFS) of Chemotherapy combined with SHR-1316 in patients with advanced esophageal squamous cell cancer.

Conditions

  • Advanced Esophageal Squamous Cell Cancer

Interventions

DRUG

Irinotecan liposome

Irinotecan liposome intravenous infusion will be administered during the first day of treatment.

DRUG

SHR-1316

SHR-1316 intravenous infusion will be administered during the first day of treatment.

DRUG

Fluorouracil

Fluorouracil intravenous infusion will be administered during the first day of treatment.

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jing Huang · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-30
Primary Completion
2019-11-30
Completion
2020-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03732508 on ClinicalTrials.gov